Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Govt’s Policy Blueprint Will Lead to Soaring R&D Costs, More Early-Stage Projects: JPMA Drug Evaluation Chief
Drug makers’ R&D spending will balloon due to a new generic target and other measures included in the government’s 2015 economic and fiscal policy guidelines adopted in June, and together with the establishment of the Japan Agency for Medical Research…
To read the full story
Related Article
- JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Introduction of GDP Guideline Would Require Investment in Distribution Systems: JPMA Quality Chief
August 19, 2015
- JPMA IP Committee Chair Predicts “Minimum Standard” for Data Protection Period for Drugs
August 5, 2015
- “All-Japan” System Needed to Contend with Top Global Drug Makers: JPMA R&D Head
August 3, 2015
- “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
July 10, 2015
ORGANIZATION
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- FPMAJ Calls for Greater Support for Stable Drug Supplies in Honebuto Policy
May 22, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
- Awareness of HPV Vaccination for Males Stands at 39.4%: Survey
May 21, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…